By: Ada Seldin – An impending storm is threatening to stagger the health care system and the nation at large. Alzheimer’s disease, which now affects as many as 5.1 million Americans, is projected to triple its toll by 2050, to 13.8 million Americans.1 These sky-rocketing rates can be attributed to aging of the ‘baby boomers.’2…

By: Lunbao (Jerry) Huang, Pharm.D. Candidate c/o 2013 – Donepezil, brand name Aricept®, is an acetylcholinesterase inhibitor indicated as monotherapy for Alzheimer’s disease, the most common form of dementia.  Cholinergic deficiency in the cortex and basal forebrain contributes to cognitive deficits in these patients.  Donepezil reversibly, noncompetitively inhibits centrally active acetylcholinesterase, the enzyme responsible for…

By: Charles George, Pharm.D. – Charles George, Pharm.D. is a recent graduate from the University of Florida in 2011.  He currently works as a community pharmacist for Walgreens Pharmacy in the Central Florida area.  Since graduation, his daily interaction with patients revealed the need for pharmacists to adapt to the evolving role of community pharmacy. …